Ausun Pharm(SH:603229)2023-04-27 16:00Financial Performance - The company's operating revenue for 2022 was approximately ¥764.55 million, representing a 34.20% increase compared to ¥569.70 million in 2021[23]. - The net profit attributable to shareholders for 2022 was approximately ¥235.38 million, a 61.29% increase from ¥145.93 million in 2021[23]. - The basic earnings per share for 2022 was ¥0.59, up 63.89% from ¥0.36 in 2021[24]. - The weighted average return on equity increased to 17.36% in 2022, up 5.09 percentage points from 12.27% in 2021[24]. - The net cash flow from operating activities decreased by 30.67% to approximately ¥120.57 million in 2022, down from ¥173.90 million in 2021[23]. - Total assets at the end of 2022 were approximately ¥2.32 billion, a 25.87% increase from ¥1.84 billion at the end of 2021[23]. - The company reported a quarterly revenue of ¥205.11 million in Q1 2022, with a total of ¥186.63 million in Q4 2022[25]. - Non-recurring gains and losses for 2022 totaled approximately ¥8.45 million, compared to ¥12.47 million in 2021[28]. - The company experienced a significant increase in net profit after deducting non-recurring items, which rose to approximately ¥226.92 million in 2022, a 70.03% increase from ¥133.46 million in 2021[23]. Dividend and Capital Structure - The company plans to distribute a cash dividend of RMB 1.12 per 10 shares, totaling RMB 47,445,551.10, based on a total share capital of 423,620,992 shares[5]. - The company intends to increase its share capital by 169,448,397 shares through a capital reserve transfer, resulting in a new total share capital of 593,069,389 shares[5]. Audit and Compliance - The company has received a standard unqualified audit report from Tianjian Accounting Firm[4]. - The board of directors guarantees the authenticity, accuracy, and completeness of the annual report[9]. - There are no non-operating fund occupations by controlling shareholders or related parties[7]. - The company has not violated decision-making procedures for external guarantees[8]. - The company has not reported any non-standard audit opinions from the accounting firm[191]. Research and Development - R&D investment reached 67.07 million yuan, representing 8.77% of operating revenue[37]. - The company has a research and development team of 253 members, including PhDs and Masters, focusing on various advanced technologies and product quality[62]. - The company is actively developing a new Class 1 drug, Brozospan Sodium, which has completed Phase II clinical trials and is awaiting Phase III[63]. - The company has established a strong presence in the international market, recognized as a strategic supplier by several large pharmaceutical companies in the US, Europe, and Japan[55]. - The company maintains a "R&D-driven sales" strategy, focusing on optimizing existing products and developing new ones[108]. Market and Industry Trends - The global pharmaceutical market is projected to grow from $1,208.4 billion in 2017 to $1,718.8 billion by 2025, with a compound annual growth rate (CAGR) of 5.2%[40]. - The global CRO market is expected to grow from $71.9 billion in 2021 to $95.2 billion in 2023, with a CAGR of 8.70%[42]. - The Chinese pharmaceutical market expanded from ¥1,430.4 billion in 2017 to ¥1,591.2 billion in 2021, with a CAGR of 2.7%, projected to reach ¥2,064.5 billion by 2025 and ¥2,739 billion by 2030[44]. - The aging population in China increased from 140 million in 2014 to 210 million in 2022, representing approximately 14.86% of the total population[49]. Environmental and Social Responsibility - In 2022, the company invested 31.97 million yuan in environmental protection initiatives[173]. - The company has established a wastewater treatment system with a capacity of 600 tons per day and an organic waste gas RTO incineration device with a capacity of 38,000 cubic meters per hour[176]. - The company reported a total investment of 1.00 million yuan in external donations and public welfare projects[182]. - A total investment of 5.80 million yuan was made in poverty alleviation and rural revitalization projects during the reporting period[182]. - The company has not faced any administrative penalties due to environmental issues during the reporting period[181]. Governance and Management - The company has appointed Tianjian Accounting Firm as the auditor with a remuneration of 550,000 RMB for the audit services[193]. - The company has established a comprehensive internal control system to ensure effective management and oversight of subsidiaries[170]. - The company has a history of appointing representatives to multiple investment management partnerships since 2014[144]. - The company has been actively expanding its board with independent directors to strengthen its governance framework[145]. - The remuneration for directors and senior management is based on performance assessments tied to the company's operational goals[146].